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Daniel Gomez3, Radhe Mohan2,5, Mary Martel2,5, Tina Briere  2,5 & Laurence Court2,5
Personalized cancer therapy seeks to tailor treatment to an individual patient’s biology. Therefore, 
a means to characterize radiosensitivity is necessary. In this study, we investigated radiosensitivity 
in the normal esophagus using an imaging biomarker of radiation-response and esophageal toxicity, 
esophageal expansion, as a method to quantify radiosensitivity in 134 non-small-cell lung cancer 
patients, by using K-Means clustering to group patients based on esophageal radiosensitivity. 
Patients within the cluster of higher response and lower dose were labelled as radiosensitive. This 
information was used as a variable in toxicity prediction modelling (lasso logistic regression). The 
resultant model performance was quantified and compared to toxicity prediction modelling without 
utilizing radiosensitivity information. The esophageal expansion-response was highly variable between 
patients, even for similar radiation doses. K-Means clustering was able to identify three patient 
subgroups of radiosensitivity: radiosensitive, radio-normal, and radioresistant groups. Inclusion of 
the radiosensitive variable improved lasso logistic regression models compared to model performance 
without radiosensitivity information. Esophageal radiosensitivity can be quantified using esophageal 
expansion and K-Means clustering to improve toxicity prediction modelling. Finally, this methodology 
may be applied in clinical trials to validate pre-treatment biomarkers of esophageal toxicity.
Currently, cancer therapy is rapidly moving towards personalization of treatment for individual patients1–3. This 
is particularly true in radiation oncology as radiomics and radiogenomics are active areas of research, specifically 
as pre-treatment biomarkers of treatment outcomes with particular focus on tumor control4–9. The other aspect 
of radiation therapy outcomes, namely normal tissue toxicity, must also be considered in personalized cancer 
therapy utilizing radiation10. In many cases, normal tissue side effects limit the safely deliverable dose to the 
malignancy.
Normal tissue toxicities are of particular concern in the treatment of non-small cell lung cancer (NSCLC), 
were acute radiation esophagitis is a dose-limiting side effect11–13. Radiation esophagitis is a common toxicity 
that greatly reduces patient quality of life14. In addition to negatively affecting outcomes by limiting tumor dose, 
radiation esophagitis can lead to interruption of treatment which also negatively affects treatment outcomes15. 
Therefore, the normal tissue toxicity, also referred at as the response, in terms of radiation esophagitis, on an indi-
vidual basis, further advances the personalization of cancer treatment, and also has the potential to considerably 
improve treatment outcomes and patient quality of life.
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One hurdle to elucidating if a potential biomarker has utility in characterizing dose-response in terms of radi-
ation esophagitis, is the manner in which we quantify the toxicity. Typically, pre-treatment biomarkers of toxicity 
are investigated in multivariate predictive models by comparing models using the pre-treatment biomarker to 
models not utilizing the respective biomarker in the model. These models will have an outcome, toxicity severity 
in our case, and biomarkers are validated if the comparison shows a large improvement in predictive performance 
of the model by including the pre-treatment biomarker. To date, some studies have shown certain single nucle-
otide polymorphisms (SNPs) as potential pre-treatment biomarkers of radiation sensitivity using the methods 
previously described10, 16–21.
Traditionally, grading criteria such as the common terminology criteria for adverse events (CTCAE) has been 
a typical clinical method of quantifying toxicity22. While this has great practical importance in terms of clinical 
symptom management, the use of grading criteria is suboptimal for the use of outcome assessment via predictive 
models, as well as for investigating pre-treatment biomarkers. This is because grading criteria assign a nominal 
score for toxicity severity based on the patient’s perceived symptom severity and physician chosen interventions, 
which are subjective in nature and are non-continuous quantifications11. This concern highlights the need for 
objective endpoint measures of toxicity severity, as well as endpoints for outcome assessment that directly relate 
to the individual patient’s radiation-response in the esophagus. For these reasons, the need for objective imaging 
biomarkers has been raised in several review articles within the realm of radiation oncology23, 24.
The radiation-induced swelling response in the esophagus, deemed esophageal expansion, has been previ-
ously validated as an imaging biomarker of radiation-response and toxicity25, 26. By utilizing a baseline CT scan 
(the radiation therapy planning CT), as well as a CT scan acquired towards the end of treatment, the relative 
amount of swelling, or the expansion, can be quantified. When combined with the radiation dose information, 
a precise quantification of response is obtained from the radiation dose for a particular patient. This biomarker 
is able to objectively quantify toxicity in the esophagus, and therefore is a suitable endpoint for the validation of 
pre-treatment biomarkers of esophageal radiation sensitivity.
The goals of this study were: (i) to quantify the inter-patient variability of esophageal response, also referred 
to as the normal tissue toxicity in this study, by utilizing esophageal expansion along with the corresponding 
radiation dose to quantify individual patient’s dose-response; (ii) to determine if patient subgroups of radia-
tion sensitivity can be identified in a mathematically reproducible manner using K-Means clustering; and (iii) 
to determine if the patient radiation sensitivity subgroup information can be used in the predictive modelling 
process to improve toxicity prediction models, thereby showing feasibility for this methodology as a validation 
procedure for pre-treatment biomarkers of radiation sensitivity.
Methods and Materials
Patient Population. One hundred and thirty-four patients were identified from a prospective, randomized 
clinical trial for the treatment of stage III NSCLC with concurrent chemoradiation therapy (paclitaxel and car-
boplatin), with tumor prescription doses of 60 (n = 4), 66 (n = 28), or 74 (n = 53) Gy in 2-Gy fractions over 6–8 
weeks at University of Texas-MD Anderson Cancer Center. Radiation dose was chosen as the maximum of the 
three prescriptions that met critical structure constraints. These constraints included: mean lung dose ≤22 Gy, 
lung volume receiving ≥20 Gy up to 40%, mean esophageal dose ≤45 Gy, 33% of esophageal volume ≤65 Gy, 
66% of esophageal volume ≤55 Gy, maximum spinal cord dose ≤50 Gy to any 2 cm3 volume, and mean heart 
dose ≤33 Gy. The inclusion/exclusion criteria included: pathologically proven, unresected stage II–IIIB NSCLC, 
suitability of concurrent chemo radiation therapy for treatment, age between 18 and 85 years, informed consent 
obtained before enrollment; small-cell histology, prior radiotherapy to the thoracic region, pregnancy. Intensity-
modulated radiation therapy (IMRT) and passive-scatter proton therapy (PSPT) was utilized in 85 and 49 of the 
study patients, respectively. During radiation therapy, patients had weekly 4-dimensional computed tomography 
(4DCT) imaging and prospective esophagitis scoring according to Common Terminology Criteria for Adverse 
Events version (CTCAE) 3.0. Our study was approved by the University of Texas-MD Anderson Cancer Center 
Institutional Review Board, including obtaining informed consent for all study patients, and was compliant with 
Health Insurance Portability and Accountability Act (HIPAA) regulations. A summary of study patient demo-
graphics is shown in Table 1.
CT scans were acquired on General Electric Lightspeed Discovery ST, Lightspeed RT16 (GE Healthcare, 
Waukesha, WI), or Philips Brilliance 64 (Philips Healthcare, Bothell, WA) CT scanners operated at 120 kV. Voxel 
dimensions were 0.98 × 0.98 × 2.50 mm in the right-left direction, anterior-posterior, and superior-inferior direc-
tion, respectively, with a 512 × 512-pixel area. Patient treatment planning and segmentation was conducted using 
the Pinnacle treatment planning system (Phillips Healthcare), with esophageal contours segmented from the 
cricoid cartilage to the gastroesophageal junction, in the axial plane, with Pinnacle version 9.8.
Quantification of Esophageal Response. Esophageal expansion was previously validated as a 
radiation-response measure in the esophagus25. Expansion is a surrogate quantification of esophageal swelling 
that is measured from relative volume change, as represented by a corresponding pair of 4DCTs (radiotherapy 
planning CT and CT acquired at the end of radiation therapy). An example of esophageal expansion is illustrated 
in Fig. 1.
The expansion-response for a given patient was quantified as the mean expansion and corresponding mean 
delivered radiation dose, to an isotropic esophageal sub-volume, centered at the slice location of maximum axial 
expansion. To maintain uniform sampling, expansion was quantified at the imaging time point nearest fraction 
30 (mean = 30.5, standard deviation = ±2.2). Delivered dose was quantified as the voxel dose at the time of the 
expansion quantification; this is typically less than the planning dose, as fraction 30 was not the last fraction of 
treatment for many of the study patients. The combination of expansion value and corresponding delivered dose 
at the time of expansion quantification is the expansion-response for a given patient.
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  No. of Males 75
  No. of Females 59
Histologic findings
  Squamous cell carcinoma 47
  Adenocarcinoma 75




















Table 1. Demographics of study patients (n = 134).
Figure 1. An example of esophageal expansion. (Top) Example patient thoracic CT with a colorwash of the 
radiation therapy dose distribution and esophageal segmentation (blue). (Bottom) Axial profile of esophageal 
expansion calculated at along the superior-inferior direction of the esophagus. The shaded red box is the 
esophageal subvolume region of analysis. Note the high expansion in the corresponding region of high 
radiotherapy dose.
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The underlying premise in utilizing clustering to identify patient sub-groups of differing radiosensitivity is 
that a particular cluster must have a proportionally higher expansion per delivered dose than other clusters. Based 
on the previous assumption, we assume that the 3 following clusters should be observed based on radiosensitivity: 
the radiosensitive cluster, which has the highest expansion per delivered dose; the radioresistant cluster, which 
has high delivered dose, but proportionally lower expansion than the radiosensitive group; and third, the radion-
ormal cluster, which has lower expansion and delivered dose than the two other clusters.
The expansion dose-response quantified at the end of treatment, around fraction 30, were clustered separately 
using a K-Means mixture model27. This method is a variation of clustering using Gaussian mixture modelling, 
which is a process of identifying membership of the patients to a finite number of unique clusters, based on the 
assumption that the observed data distribution is a collection of multiple Gaussian distributions. These unique 
underlying Gaussian distributions are representative of the patient radiosensitivity clusters we seek to identify.
K-Means clustering is a commonly utilized technique where the squared Euclidean distance is used as a dis-
similarity measure27–29. Minimization of dissimilarity for data points (patients) in a given number of clusters 
is used to find the solution. Once minimized, the patients are clustered into unique groups based on Gaussian 
mixture modeling of the expansion-response.
Before clustering was calculated, patients with a sub-volume dose less than 20 Gy were excluded from the 
analysis (n = 8). This is because there was insufficient dose to incite an expansion-response. All excluded patients 
were asymptomatic. After clustering the remaining 126 patients, the radiosensitive patient cluster was identified 
and then used in the toxicity prediction modelling process.
Toxicity Prediction Modelling. In this study, least absolute shrinkage and selection operator (lasso) logis-
tic regression was utilized to create the toxicity prediction models. These models were then used to determine 
if the radiosensitivity cluster membership substantially improves esophagitis prediction modelling. Lasso logis-
tic regression is a robust model building method that prevents overfitting28, 30. Lasso toxicity prediction mod-
els were constructed with the 126 study patients that had adequate esophageal dose for analysis in a repeated 
cross-validation procedure, for 1000 iterations, which is illustrated in Fig. 2. The repeated cross-validation  pro-
cedure yields an accurate representation of model generalizability and reduces the effect of random partitioning 
of patient data28, 30, 31.
To summarize this procedure, predictor variables in the form of dosimetric and clinical factors were used as 
covariates to create toxicity prediction models for ≥grade 3 esophagitis complication, according to CTCAE ver-
sion 3.0. Approximately 75% of the patients are randomly drawn into a training set, which builds the prediction 
model. The remaining 25% of patients comprise the test set and are used to quantify the built model’s predictive 
performance in the form of area under the curve (AUC) and Brier scores. This process is repeated for 1000 itera-
tions to remove any influence of random draw of  patients for the training or tests sets. The dosimetric and clinical 
factors utilized as covariates in the models are shown in Table 2. The recurrence of model features was quantified 
by recording variables in each model, for every iteration of the cross-validation procedure.
The prediction model construction process was then repeated with radiosensitivity as an additional covari-
ate. The previously described clustering technique was used to identify patients that had proportionally higher 
expansion-response then other study patients, and this information was quantified as a dichotomous variable (1 
for radiosensitive patient, 0 otherwise) in the LASSO toxicity prediction modelling construction process. Model 
performance was assessed and recurring model predictors were cataloged for every iteration of the model con-
struction process. The results of both model construction scenarios (with and without the radiosensitivity pre-
dictor) were compared.
Computational Implementation. Predictor variables were standardized by subtracting the mean vari-
able value of all patients from each individual patient value, and then dividing the result by the standard devia-
tion32. All computations were conducted in MATLAB version 8.2 (Mathworks, Natick, MA). K-Means clustering 
was computed using MATLAB’s Statistics and Machine Learning toolbox. Lasso models were constructed using 
the open source glmnet package implemented in MATLAB33. A p-value of p < 0.05 was considered statistically 
significant.
Figure 2. Illustration of the iterative toxicity prediction model construction process using repeated cross-
validation.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 6034  | DOI:10.1038/s41598-017-05003-x
Results
Expansion-Response and Radiosensitivity Clustering. The expansion-response quantified towards 
the end of treatment is described for all 134 study patients in Fig. 3A. An overall trend of increasing toxicity 
severity along with dose is observed, but this has high patient-to-patient variability for a given dose range. 
Additionally, the expansion per delivered dose is also markedly variable. The distribution of expansion in 10-Gy 
dose partitions, from 20 Gy to 70 Gy, is shown in Fig. 3B, with a high variance of expansion observed for patients 
with similar doses. The standard deviation of expansion in a given dose partition is also shown, with a 30% stand-
ard deviation of expansion being typical.
The 8 patients excluded from the clustering and toxicity analyses can be identified in Fig. 3A as the patients 
with mean sub-volume doses under 20 Gy. The resultant K-Means clustering of the expansion-response is shown 
in Fig. 3C. The clusters are shown by color, with the radiosensitive cluster as brown, the radio-normal cluster is 
green, and the radioresistant cluster is purple. The assigned clusters’ radiation sensitivity characteristics met the 
necessary assumptions of expansion-response described in the methods section. Distributions of toxicity severity 
according to cluster membership is shown in Fig. 3D. No grade 0 patients were found in the radiosensitive cluster, 
but many grade 2 and 3 patients were. The radioresistant (purple) cluster contained the most patients, and all 
esophagitis grades being observed within this cluster.
The lasso toxicity prediction model construction procedure had similar distributions of recurring model 
predictors, even for toxicity models not using radiosensitivity as a predictor variable. The results of predictor 
recurrence for models constructed without and with the radiosensitivity variable are shown in Fig. 4A and B, 
respectively. For models constructed with the radiosensitivity variable, this predictor was the most recurring vari-
able and was chosen in over 99% of the 1000 iterations of model construction (top most data bar in Fig. 4B). Mean 
esophageal dose was the second most recurring predictor in the radiosensitivity information inclusive models 
and the most recurring predictor in models not including the radiosensitivity information.
The toxicity prediction model performance with and without radiosensitivity information is summarized in 
Table 3. Models utilizing radiation sensitivity information using K-Means clustering to identify radiosensitive 





1 Smoking Status 28 LE6025%
2 Induction Chemotherapy 29 LE5025%
3 GTV 30 LE4025%
4 Histology-other 31 LE3025%
5 Histology-Large Cell 32 LE2025%
6 Histology-Adenocarcinoma 33 LE1025%
7 Histology-Squamous Cell 34 V70
8 Nodal Involvement 35 V65
9 Stage-IV 36 V60
10 Stage-IIIB 37 V55
11 Stage-IIIA 38 V50
12 Stage-IIB 39 V45
13 Stage-IIA 40 V40
14 Tumor Location-Left Lateral 41 V35
15 Tumor Location-Right Lateral 42 V30
16 Tumor Location-Left Medial 43 V25
17 Tumor Location-Right Medial 44 V20
18 Tumor Location-Left Upper 45 V15
19 Tumor Location-Right Upper 46 V10
20 Gender 47 MED
21 Age 48 Dmax
22 LE60100% 49 Prescription Dose





Table 2. Predictor variables used in the NTCP model construction process. Abbreviations: MED = mean 
esophagus dose; Dmax = maximum esophagus dose; V10 = volume of esophagus receiving at least 10 Gy; 
LE1025% = esophageal length with at least 10 Gy to at least 25% of the cross-sectional area to axial slice of the 
esophagus; LE10100% = esophageal length with at least 10 Gy to at least 100% of the cross-sectional area to axial 
slice of the esophagus.
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models using clustering have significantly higher AUCTraining and AUCTest (paired T-test on AUC values for each 
corresponding iteration of cross-validation, p < 0.05), than models not using radiation sensitivity information. 
Both types of Brier scores were optimal (lower value) for the clustering/radiosensitivity models compared to 
models without radiosensitivity information.
Discussion
In this study, K-Means clustering was performed on esophageal expansion-response to identify patients’ inherent 
radiosensitivity. Clustering was calculated using expansion-response at approximately the 30th radiation therapy 
treatment fraction. This information was then used to identify radiosenstive patients, and this information was 
then converted to a dichotomous variable. This radiosensitivity information was used in the toxicity prediction 
modelling process in an attempt to improve esophagitis prediction models, using lasso penalized logistic regres-
sion in a repeated cross-validation procedure.
The expansion-response of these patients was highly variable regardless of delivered esophageal dose. For 
similar subvolume doses, many patients had vastly different amounts of expansion, in addition to varying toxicity 
severity. This shows a potential pitfall of toxicity prediction modelling without accounting for inherent radiation 
sensitivity, where variability of patients’ response outweighs the study population’s average observed response. 
The variability of response for patients with similar delivered dose may make detecting such effects arduous if 
patient radiosensitivity is not considered.
Toxicity prediction models using radiosensitivity predictor variables outperformed toxicity models not uti-
lizing radiosensitivity information, for a grade 3 maximum esophagitis endpoint. The performance of models 
Figure 3. (A) Plot of expansion-response at the end of radiation therapy (approximately fraction 30) in the 
analyzed subvolume of the esophagus for 134 study patients. Patient markers denote maximum esophagitis 
grade during treatment. (B) Boxplot of the distribution of mean subvolume esophageal expansion, grouped 
according to mean subvolume doses of 20 to 30 Gy, 30 to 40 Gy, 50 to 60 Gy, and 60 to 70 Gy, for 126 study 
patients with the expansion-response quantified around treatment fraction 30. The standard deviation of 
expansion in each dose group is shown above each box. The edges of the box represent the quartile values of 
expansion, with the red line within each box representing that groups median expansion value. The range 
of values is represented by the black whiskers and the red ‘+’ denotes outliers (values beyond 1.5 times 
the interquartile range from the edge of the box). (C) Patient membership in radiosensitivity clusters after 
application of K-Means clustering on the expansion-response of the patient population. (D) Table of the 
characteristics of clustering membership for K-Means clustering for expansion-response at the end of radiation 
therapy for the 126 patients analyzed in the cluster analysis.
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using radiosenstivity information is even more impressive, as a total of eight low-dose, low-response, and asymp-
tomatic patients were excluded from the model construction process. In typical modelling scenarios, these types 
of patients are easily classified and will contribute to a higher model performance metric value, which would 
be reflected in the quantification of predictive ability. By not including these patients, the modelling situation 
is more challenging for the classification of esophagitis severity. Since the toxicity models with radiosensitivity 
information had high predictive ability despite this challenging scenario, this translated into more robust toxicity 
prediction models when including the radiosensitivity information.
A prime application of the framework presented in this study, is the use the use of radiosenstivity, as quantified 
by the expansion dose-response, as a validation methodology for clinical trials. With the push into radiogenomics 
and a desire to quantify pre-treatment biomarkers to aid in personalized medicine, the question of how to validate 
such pre-treatment biomarkers arises. Traditional esophagitis grade endpoints are quite subjective and variable, 
and do not objectively quantify radiation-response. Since esophageal expansion is an objective radiation-response 
biomarker, we can utilize the expansion-response to validate any prospectively investigated pre-treatment bio-
marker of radiation-response, when esophageal response is a trial endpoint. A simple workflow of this concept 
is shown in Fig. 5. Furthermore, this validation methodology could be applied to any situation that prospectively 
investigates any two radiation therapy treatments (different modality, fractionation scheme, etc.) to objectively 
validate any difference in radiation-response in the esophagus.
Figure 4. Bar charts of the occurrence of predictors for all 1000 iterations of the LASSO logistic regression 
toxicity prediction- modelling construction process. Models created without the radiosensitivity predictor 
are described in (A), and models using the radiosensitive tag variable from K-Means clustering of expansion-
response at the end of radiotherapy are shown in (B). The predictor index number identifies the specific 
predictor variable from Table 2.
Model Type AUCTraining (S.D.) AUCTest (S.D.) Brier Score Scaled Brier (%)
No Clustering 0.842 (±0.065) 0.693 (±0.099) 0.175 (±0.020) 18.2 (±12.0)
K-Means Clustering 0.907 (±0.055) 0.753 (±0.094) 0.151 (±0.019) 12.1 (±11.2)
Model Type Top Recurring Predictors
No Clustering MED, LE50Gy100%, Left Medial, LE60Gy100%, Smoking Status
K-Means Clustering RS Tag, MED, LE60Gy100%, Smoking Status, Left Medial, Age
Table 3. Results of the lasso logistic regression toxicity prediction model construction process with and without 
using K-Means clustering to identify radiosensitive patients, from expansion-response quantified at the end of 
radiation therapy, for a total of 126 study patients. S.D. – Standard Deviation. The highest recurring predictors 
from all 1000 iterations of the model construction process are listed from highest to lowest recurring. Standard 
deviation of AUC values are listed in parentheses.
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This work was not without limitations. The clustering process is unsupervised in terms of esophagitis outcome, 
and therefore requires some assumptions for interpretation. As described in the methods, the cluster assignment 
of radiosensitivity was determined based on the assumptions of the relative expansion-response within the study 
population. It is vital to validate these findings on an external dataset, as it would be interesting to see if cluster 
assignment and shape would vary with new patient data. Another limitation was that the radiosensitivity infor-
mation was only used dichotomously (radiosensitive or not radiosensitive). It would be of interest to analyze the 
utility of not just the radiosensitive clusters, but also patients labelled as radionormal and radioresistant. The 
radioresistant cluster in particular would be of interest in dose-escalation studies.
In addition to expansion, other types of imaging biomarkers of radiation-response can be used in a similar 
methodology as the work presented in this study. Esophageal uptake from 18F-fluorodeoxyglucose positron emis-
sion tomography (FDG-PET) has been shown to quantify radiation-response and toxicity in the esophagus34, 35. 
Therefore, it is feasible to apply esophageal FDG uptake with the clustering methodology to identify patients with 
inherent radiation sensitivity in the esophagus. Another application of this work is the analysis of any potential 
variation of radiosensitivity along the axial length of the esophagus. With a controlled cohort similarly irradiated 
along different axial regions of the esophagus, it may possible to determine any variability in response between 
specific esophageal sub-regions.
In conclusion, clustering techniques can be applied to the expansion-response mechanism to determine 
patient radiosensitivity. This radiosensitivity information can be used in the esophagitis prediction modelling 
process to improve toxicity prediction performance. Patient inherent radiosensitivity can be assessed towards the 
end of radiation therapy and may be applicable for outcome assessment in clinical trials that investigate response 
in the esophagus.
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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